These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Broad Next-Generation Integrated Sequencing of Myelofibrosis Identifies Disease-Specific and Age-Related Genomic Alterations. Kandarpa M; Robinson D; Wu YM; Qin T; Pettit K; Li Q; Luker G; Sartor M; Chinnaiyan A; Talpaz M Clin Cancer Res; 2024 May; 30(9):1972-1983. PubMed ID: 38386293 [TBL] [Abstract][Full Text] [Related]
3. [Genetic characteristics and prognostic values of RAS mutations in patients with myelofibrosis]. Wu JY; Li B; Jia YJ; Zhang PH; Xu ZF; Qin TJ; Qu SQ; Pan LJ; Liu JQ; Yan X; Zhang YD; Chen J; Gong JY; Xiao ZJ Zhonghua Xue Ye Xue Za Zhi; 2020 Dec; 41(12):989-995. PubMed ID: 33445845 [No Abstract] [Full Text] [Related]
4. Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group. Rotunno G; Pacilli A; Artusi V; Rumi E; Maffioli M; Delaini F; Brogi G; Fanelli T; Pancrazzi A; Pietra D; Bernardis I; Belotti C; Pieri L; Sant'Antonio E; Salmoiraghi S; Cilloni D; Rambaldi A; Passamonti F; Barbui T; Manfredini R; Cazzola M; Tagliafico E; Vannucchi AM; Guglielmelli P Am J Hematol; 2016 Jul; 91(7):681-6. PubMed ID: 27037840 [TBL] [Abstract][Full Text] [Related]
5. [Analysis of prognostic factors in Chinese patients with post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis]. Chen M; Xu ZF; Xu JQ; Li B; Zhang PH; Qin TJ; Zhang Y; Wang JY; Zhang HL; Fang LW; Pan LJ; Hu NB; Qu SQ; Xiao ZJ Zhonghua Xue Ye Xue Za Zhi; 2016 Oct; 37(10):876-880. PubMed ID: 27801320 [TBL] [Abstract][Full Text] [Related]
6. EZH2 mutational status predicts poor survival in myelofibrosis. Guglielmelli P; Biamonte F; Score J; Hidalgo-Curtis C; Cervantes F; Maffioli M; Fanelli T; Ernst T; Winkelman N; Jones AV; Zoi K; Reiter A; Duncombe A; Villani L; Bosi A; Barosi G; Cross NC; Vannucchi AM Blood; 2011 Nov; 118(19):5227-34. PubMed ID: 21921040 [TBL] [Abstract][Full Text] [Related]
7. Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis. Masarova L; Bose P; Daver N; Pemmaraju N; Newberry KJ; Manshouri T; Cortes J; Kantarjian HM; Verstovsek S Leuk Res; 2017 Aug; 59():110-116. PubMed ID: 28601551 [TBL] [Abstract][Full Text] [Related]
8. [Analysis of the effect of gene mutations on the efficacy of ruxolitinib in patients with myelofibrosis based on second-generation sequencing technology]. Tan YX; Luo J; Huang JX; Luo DM; Liang HY; Zhou X; Liu XL; Xu N Zhonghua Xue Ye Xue Za Zhi; 2022 Apr; 43(4):323-329. PubMed ID: 35680632 [No Abstract] [Full Text] [Related]
9. Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management. Tefferi A Am J Hematol; 2023 May; 98(5):801-821. PubMed ID: 36680511 [TBL] [Abstract][Full Text] [Related]
10. Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes. Stein BL; Williams DM; O'Keefe C; Rogers O; Ingersoll RG; Spivak JL; Verma A; Maciejewski JP; McDevitt MA; Moliterno AR Haematologica; 2011 Oct; 96(10):1462-9. PubMed ID: 21712540 [TBL] [Abstract][Full Text] [Related]
11. [Clinical Significance of RAS Gene Mutations in Patients with Acute Myeloid Leukemia]. Wei JF; Qiu HY; Chen Z; Miao L; Wang Y; Zhao LD; Cai ZM Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Oct; 30(5):1391-1396. PubMed ID: 36208240 [TBL] [Abstract][Full Text] [Related]
14. Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations. Andrikovics H; Krahling T; Balassa K; Halm G; Bors A; Koszarska M; Batai A; Dolgos J; Csomor J; Egyed M; Sipos A; Remenyi P; Tordai A; Masszi T Haematologica; 2014 Jul; 99(7):1184-90. PubMed ID: 24895336 [TBL] [Abstract][Full Text] [Related]
15. Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study Palandri F; Palumbo GA; Iurlo A; Polverelli N; Benevolo G; Breccia M; Abruzzese E; Tiribelli M; Bonifacio M; Tieghi A; Isidori A; Martino B; Sgherza N; D'Adda M; Bergamaschi M; Crugnola M; Cavazzini F; Bosi C; Binotto G; Auteri G; Latagliata R; Ibatici A; Scaffidi L; Penna D; Cattaneo D; Soci F; Trawinska M; Russo D; Cuneo A; Semenzato G; Di Raimondo F; Aversa F; Lemoli RM; Heidel F; Reggiani MLB; Bartoletti D; Cavo M; Catani L; Vianelli N Semin Hematol; 2018 Oct; 55(4):248-255. PubMed ID: 30502854 [TBL] [Abstract][Full Text] [Related]
16. The evolving understanding of prognosis in post-essential thrombocythemia myelofibrosis and post-polycythemia vera myelofibrosis vs primary myelofibrosis. Masarova L; Verstovsek S Clin Adv Hematol Oncol; 2019 May; 17(5):299-307. PubMed ID: 31188809 [TBL] [Abstract][Full Text] [Related]
17. Detection of CALR Mutation in Clonal and Nonclonal Hematologic Diseases Using Fragment Analysis and Next-Generation Sequencing. Gardner JA; Peterson JD; Turner SA; Soares BL; Lancor CR; Dos Santos LL; Kaur P; Ornstein DL; Tsongalis GJ; de Abreu FB Am J Clin Pathol; 2016 Oct; 146(4):448-55. PubMed ID: 27686171 [TBL] [Abstract][Full Text] [Related]
18. Comparison of the Mutational Profiles of Primary Myelofibrosis, Polycythemia Vera, and Essential Thrombocytosis. Song J; Hussaini M; Zhang H; Shao H; Qin D; Zhang X; Ma Z; Hussnain Naqvi SM; Zhang L; Moscinski LC Am J Clin Pathol; 2017 May; 147(5):444-452. PubMed ID: 28419183 [TBL] [Abstract][Full Text] [Related]
19. Current Concepts of Pathogenesis and Treatment of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms. Zeeh FC; Meyer SC Hamostaseologie; 2021 Jun; 41(3):197-205. PubMed ID: 34192778 [TBL] [Abstract][Full Text] [Related]
20. Next-generation sequencing with a 54-gene panel identified unique mutational profile and prognostic markers in Chinese patients with myelofibrosis. Gill H; Ip HW; Yim R; Tang WF; Pang HH; Lee P; Leung GMK; Li J; Tang K; So JCC; Leung RYY; Li J; Panagioutou G; Lam CCK; Kwong YL Ann Hematol; 2019 Apr; 98(4):869-879. PubMed ID: 30515541 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]